Business Wire

CHICAGO--(BUSINESS WIRE)-- Tempus, a leader in artificial intelligence and precision medicine, today announces an expansion of its collaboration with AstraZeneca, which leverages Tempus Next to arm physicians with technology that supports the delivery of guideline-directed biomarker testing for patients with non-small cell lung cancer (NSCLC). The magnitude and frequency of updates to oncology guidelines each year make it difficult for the updates to be rapidly... (continue reading...)

TORONTO--(BUSINESS WIRE)-- Postmedia Network Inc., a wholly owned subsidiary of Postmedia Network Canada Corp. (“Postmedia” or “the Company”) today announced that it has closed its previously announced sale of the Winnipeg Sun, The Graphic Leader, Kenora Miner & News and the Winnipeg Press Commercial Print division to the Klein Group Ltd. (the “Klein Group”).

About Postmedia Network Canada Corp.

Postmedia Network Canada Corp. (TSX:PNC.A, PNC.B) is... (continue reading...)

Ankyra Therapeutics will provide an update on the status of the ANK-101 Phase 1 ANCHOR clinical trial at ASCO 2024 and has received approval by FDA and Health Canada to amend the Phase I study to include patients with solid tumors in visceral organs

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ankyra Therapeutics, a clinical-stage oncology company developing anchored immunotherapies to improve the therapeutic window for immuno-oncology drugs, announced today that it is... (continue reading...)

NEW YORK--(BUSINESS WIRE)-- Since 2019, Sally Hansen® has committed to partnering with GLAAD to support Pride and the organization’s mission to accelerate acceptance for the LGBTQ+ community. In the spirit of Pride 2024, this year’s NEW Sally Hansen® x Pride Limited-Edition Collection includes 11 metallic shades of the Progress Pride flag and 3 Salon Effects® Perfect Manicure designs modeled after the Trans, Bi, and Progress Pride flag!

The new Sally Hansen... (continue reading...)

Tumors shrank in 91% of taletrectinib-treated patients with advanced ROS1-positive NSCLC who were ROS1 TKI-naïve and 52% of those who were ROS1 TKI-pretreated in the study

Responses were durable with long-term follow-up; 71% of TKI-naïve patients were still progression-free at two years

TRUST-I is one of two registrational Phase 2 studies evaluating taletrectinib for the treatment of patients with advanced ROS1-positive NSCLC

NEW YORK--(BUSINESS... (continue reading...)